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166 The Journal of Thoracic and CardioObjective: Large cell neuroendocrine carcinomas of the lung display morpho-
logic and immunohistochemical characteristics common to neuroendocrine tu-
mors and the morphologic features of large cell carcinomas. Surgical resection
of large cell neuroendocrine carcinomas in many series has been described, with
5-year actuarial survivals ranging from 13% to 57%. Considerable debate has
emerged as to whether these tumors should be classified and treated as non–
small cell lung cancers or small cell lung cancers. The objective of this study
was to report the outcome of surgical resection in patients with large cell
neuroendocrine carcinomas.
Methods: An analysis of our tumor registry was performed to identify all patients
undergoing surgical resection of lung cancer between July 1, 1988, and Decem-
ber 31, 2002, for large cell tumors. Cases were then segregated into large cell
neuroendocrine carcinomas, mixed large cell neuroendocrine carcinomas (in
which at least one portion of the tumor was a large cell neuroendocrine
carcinoma), or large cell carcinomas on the basis of morphology and differen-
tiation. Follow-up was complete on all patients, with a mean follow-up of 48
months. Type of resection, mortality, and survival by stage were analyzed.
Kaplan-Meier survival was determined for all patients from the date of surgical
intervention. Cox proportional hazards model analysis incorporating the vari-
ables of age, sex, histology, and stage estimated the effect of large cell neu-
roendocrine carcinomas and mixed large cell neuroendocrine carcinomas on
recurrence and death. The stage of disease in all patients was assessed according
to the 1997 American Joint Committee on Cancer guidelines.
Results: Of the 2099 patients who underwent resection, 82 (3.9%) had large cell
lung cancers. Perioperative mortality was 2.4%. Overall survival and freedom
from recurrence at 5 years for the entire group was 47.1% and 58.4%, respec-
tively. Overall survival by histologic subtype at 5 years was 30.2% for patients
with large cell neuroendocrine carcinomas (n  45), 30.3% for patients with
mixed large cell neuroendocrine carcinomas (n  11), and 71.3% for patients
with large cell carcinomas (n  21). Survival was significantly worse for
patients with large cell neuroendocrine carcinomas than for patients with large
cell carcinomas (P  .013). The presence of large cell neuroendocrine carci-
nomas in the specimen (the large cell neuroendocrine carcinoma and mixed large
cell neuroendocrine carcinoma groups combined) was significantly associated
with decreased survival (relative risk, 2.44; 95% confidence interval 1.29-4.58;
P  .003) and decreased freedom from recurrence (relative risk, 4.52; 95%
confidence interval, 1.76-11.57; P  .001).
Conclusion: Patients with large cell neuroendocrine carcinomas have a signifi-
cantly worse survival after resection than patients with large cell carcinomas,
even in stage I disease. Accurate differentiation of large cell neuroendocrine
carcinoma from large cell carcinoma is important because it identifies those
patients at highest risk for the development of recurrent lung cancer.
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TSLarge cell neuroendocrine carcinomas (LCNECs) ofthe lung display the morphologic and immunohisto-chemical characteristics common to neuroendocrine
tumors and the morphologic features of large cell carcino-
mas (LCCs). The 1999 World Health Organization Interna-
tional Association for Staging of Lung Cancer histologic
classification of lung and pleural tumors grouped a number
of histologic variants under the heading “large cell carci-
noma,” including LCNEC, combined LCNEC, basaloid car-
cinoma, lymphoepithelioma-like carcinoma, clear cell car-
cinoma, and LCC with rhabdoid phenotype.1 Although this
classification scheme placed all lung cancers with large cell
characteristics in a separate category, it did not address the
biologic behavior of these histologic variants.
Travis and colleagues2 proposed a separate category of
pulmonary neuroendocrine tumors in which LCNEC was
distinct from typical carcinoid tumors, atypical carcinoid
tumors, and small cell lung cancer (SCLC). LCNEC was
described as having a cell size at least 3 times that of SCLC,
an organoid growth pattern, cellular palisading or rosette-
like areas, a high mitotic rate, and a variably granular
chromatin pattern.3 The spectrum of neuroendocrine tumors
was further classified by Dressler and associates4 on the
basis of histologic characteristics and clinical behavior.
Grade I neuroendocrine lung cancers corresponded to clas-
sic typical carcinoid tumors. Grade II neuroendocrine lung
cancers corresponded most closely with atypical carcinoid
cancers. Grade III tumors were divided into small cell
neuroendocrine lung cancer (SCLC) and LCNEC. Regard-
less of which classification scheme is preferred, accurate
differentiation of LCNEC from other variants of non–small
cell lung cancer (NSCLC) and SCLC might be difficult and
often requires specific immunohistochemical stains for neu-
roendocrine markers.
The true incidence of LCNEC is in all probability very low,
although it has not been well defined. In a series reported by
Jiang and coworkers5 of 766 resected primary lung cancers, 22
(2.9%) were classified as LCNECs. Takei and colleagues6
reported a similar rate of 3.1% (87/2790) in their series. In
published series the overall 5-year actuarial survivals for sur-
gically resected LCNEC range from 13% to 57% (Table 1).3-11
These results appear to be substantially worse than those ob-
served in other histologic types of NSCLC. Therefore, consid-
erable debate has emerged as to whether these tumors should
be classified and treated as NSCLC or considered together with
small cell carcinoma because of their apparent aggressive
behavior. The objective of this study was to examine the effect
of LCNEC on survival after surgical resection in patients with
this histologic subtype of NSCLC.
Methods
Population Under Study
The Barnes-Jewish Hospital Cancer Registry and the Thoracic
Surgery database were queried for patients undergoing surgical
The Journal of Thoraciresection of lung cancer between July 1, 1988, and December 31,
2002, for large cell tumors. All slides of LCCs encountered during
that time were individually reviewed by one pathologist (J.H.R.)
and segregated into the categories of LCNEC, mixed LCNEC (in
which at least one portion of the tumor was LCNEC), or LCC on
the basis of morphology and differentiation. The pathologist was
blinded to the clinical data associated with the pathologic speci-
mens. Surgical pathology reports of all patients selected from this
database query were individually reviewed, and the final patho-
logic staging was assigned according to the 1997 revisions in the
International System for Staging Lung Cancer.12
Tumor recurrence, patient survival, and cause of death were
determined for each patient. Follow-up information, including
cause of death, was acquired within the last 6 months for all
patients through clinic follow-up notes, direct patient or family
contact, contact with the patient’s primary care physician, and
review of all death certificates. This study represents a secondary
data analysis of a prospective cohort study. Approval for this study
was granted from the Washington University School of Medicine
Human Studies Committee.
Statistical Analysis
Descriptive statistics were used to describe the patients’ charac-
teristics and outcomes. Kaplan-Meier (product limit) graphs were
used to demonstrate survival over time and freedom from
recurrence of disease. Survival and event-free survival compar-
isons between groups of patients were completed by the Mantel-
Haenszel log-rank test. The Cox multivariate proportional hazards
regression model was used to identify independent risk factors for
death and recurrence in the studied patient population, including
the variables of age, sex, histology, and stage. All data analysis




Of 2089 patients undergoing resection for NSCLC between
July 1, 1988, and December 31, 2002, 82 (3.9%) had large







Dressler et al4 1997 40 13% 18% (25)
Travis et al3 1998 37 27% NA
Jiang et al5 1998 22 44.8% NA
Garcia-Yuste et al8 2000 22 21% 33% (13)
Iyoda et al7 2001 50 35%* NA
Zacharias et al9 2003 20 47% 88% (9)
Takei et al6 2003 87 57% 67% (41)
Paci et al10 2004 48 21% 27% (29)
Doddoli et al11 2004 20 36% NA
LCNEC, Large cell neuroendocrine carcinoma; OS, overall survival; NA, not
applicable. *Number estimated from survival curve.cell lung cancers. Of these 82 cancers, 45 (54.9%) were
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TSclassified as LCNEC, 26 (31.7%) as LCC, and 11 (13.4%)
as mixed LCNEC. Forty-six (56%) patients were male, and
36 (44%) were female. The median patient age was 67 years
(range, 35-90 years). Operative procedures performed in-
cluded 69 lobectomies (84.1%), 6 wedge resections (7.3%),
4 pneumonectomies (4.9%), 2 sleeve resections (2.4%), and
1 segmentectomy (1.2%). Two (2.4%) patients had residual
microscopic disease at the margin after surgical resection.
The distribution of patients by pathologic stage was 54
(65.9%) in stage I, 19 (23.2%) in stage II, 8 (9.8%) in stage
III, and 1 (1.2%) in stage IV. Stage distribution according to
tumor histology is shown in Table 2. A comparison in stage
distribution between LCNEC and NSCLC treated during the
study period is shown in Table 3. No patients received
preoperative chemotherapy or radiation therapy. However,
14 patients with greater than stage I disease received adju-
vant therapy: LCNEC (8/45), LCC (1/26), and mixed
(5/11).
Survival
Survival data were collected for each patient from the date
of operation, with a mean duration of follow-up of 52.8
months. The 5-year actuarial overall survival for the entire
group was 47.1%. Survival for patients with LCNEC was
significantly lower than that observed in patients with LCC
(30.2% vs 71.3%, P  .013, Figure 1). This significant
difference in survival was also seen in patients with stage I
disease (32.1% vs 80.0%, P  .008, Figure 2). Although the
number of patients with mixed LCNEC was small, the
survival observed in these patients appeared to be similar to
that of patients with LCNEC.
The association of age, sex, tumor histology, and patho-
logic stage with survival was analyzed by Cox proportional
hazard multivariate analysis. As shown in Table 4, patients
with LCNEC and mixed LCNEC were 2.4 times more likely
TABLE 2. Pathologic staging on the basis of tumor histol-
ogy
Stage LCNEC Mixed LCNEC LCC
I 30 (66.7%) 3 (27.3%) 21 (80.8%)
II 11 (24.4%) 4 (36.4%) 4 (15.4%)
III 3 (6.7%) 4 (36.4%) 1 (3.8%)
IV 1 (2.2%) 0 0
LCNEC, Large cell neuroendocrine carcinoma; LCC, large cell carcinoma.
TABLE 3. Distribution of stages for resected patients with
IA IB
NSCLC (n  2089) 34.4% 23.8% 3
LCNEC (n  45) 48.8% 17.9% 4LCNEC, Large cell neuroendocrine carcinoma; NSCLC, non–small cell lung carc
168 The Journal of Thoracic and Cardiovascular Surgery ● Julyto die during the follow-up period than were patients with
LCC (relative risk, 2.44; 95% confidence interval, 1.29-
4.58; P  .003).
Causes of Death
Two (2.4%) patients died in the early postoperative period,
and 54 (65.9%) additional patients died during follow-up.
Of 56 mortalities in this series, 38 were the result of met-
astatic disease, 11 were from cardiac disease, 6 were from
respiratory failure, and 1 was from injuries sustained during
a motor vehicle collision.
Incidence of Recurrent Lung Cancer
Forty (48.8%) patients had recurrent lung cancer during the
follow-up period. Five-year actuarial freedom from recur-
rence for patients with LCNEC was significantly lower than
that observed in patients with LCC (39.3% vs 83.8%, P 
.003, Figure 3). This significant difference in freedom from
recurrence was also seen in patients with stage I disease
(43.5% vs 90.0%, P  .004, Figure 4). Freedom from
recurrence in patients with mixed LCNEC was similar to
that observed in patients with LCNEC.
The association of age, sex, tumor histology, and patho-
logic stage with survival was analyzed by Cox proportional
hazard multivariate analysis. As shown in Table 5, patients
with LCNEC and mixed LCNEC were 4.5 times more likely
to have recurrent lung cancer during the follow-up period
than were patients with LCC (relative risk, 4.52; 95% con-
fidence interval, 1.76-11.57; P  .001).
EC versus NSCLC
IIB IIIA IIIB IV
16.1% 13.9% 5.3% 3.1%
20.0% 6.7% 0% 2.2%
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TSDiscussion
The morphologic and phenotypic features that distinguish
LCNEC from other histologic subtypes of NSCLC have
been well described. Because survival after resection in
patients with LCNEC has been disappointingly low, there
has been considerable debate as to whether these tumors
should be classified and treated as NSCLCs or considered
together with SCLCs. The incidence of LCNEC in our
series of resected lung cancers was 2.2%, and this figure is
in agreement with those reported in other series.4-6,13 The
overall 5-year survival for patients with LCNEC treated
with surgical resection was 30%, which was significantly
lower than the survival observed in patients with LCC, with
no evidence of neuroendocrine morphology or differentia-
tion. Importantly, this significant difference was observed
even in patients with stage I disease, demonstrating the
negative effect of LCNEC histology on survival.
Figure 2. Kaplan-Meier overall survival stratified by cell type:
stage I only.
Figure 3. Kaplan-Meier recurrence-free survival stratified by cell
type.The Journal of ThoraciAlthough a wide range of 5-year survivals has been
reported for resected stage I LCNEC (18% to 88%),4,6,8-10
the 32% 5-year survival observed in this series for stage I
disease is very similar to that seen in the studies reported by
Garcia-Yuste and coworkers8 (33%) and Paci and col-
leagues10 (27%). Both Takei and associates6 and Zacharias
and coworkers9 have reported higher 5-year survivals (67%
and 88%, respectively) after surgical resection in patients
with LCNEC. The reasons for the wide variation in survival
TABLE 4. Results of multivariate analysis of prognostic
factors influencing survival for patients after surgical re-
section
Variable N Relative risk 95% CI P value
Cell type (LCNEC/mixed
LCNEC)
56 2.436 1.294-4.584 .003
Age (y) 82 1.021 1.011-1.048 .010
Stage of disease
(stage II, III, or IV)
28 1.354 0.757-2.423 .314
Sex (female) 36 1.192 0.690-2.061 .526
CI, Confidence interval; LCNEC, large cell neuroendocrine carcinoma.
TABLE 5. Results of multivariate analysis of prognostic
factors influencing disease recurrence for patients after
surgical resection
Variable N Relative risk 95% CI P value
Cell type (LCNEC/mixed
LCNEC)
56 4.515 1.763-11.565 .001
Age (y) 82 1.010 0.979-1.043 .129
Stage of disease
(stage II, III, or IV)
28 1.611 0.853-3.042 .145
Sex (female) 36 1.641 0.854-3.152 .533
Figure 4. Kaplan-Meier recurrence-free survival stratified by cell
type: stage I only.CI, Confidence interval; LCNEC, large cell neuroendocrine carcinoma.
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ers9 attributed the excellent survival observed in their study
to the use of systematic nodal dissection at the time of
resection. However, this study was relatively small (20
patients), and the 88% 5-year survival for stage I LCNEC
reported in this series was based on 9 patients.
Although the diagnosis of LCNEC can be easily made
when lung tumors have evidence of both neuroendocrine
morphology and differentiation, there often is some hesi-
tancy among pathologists to ascribe the diagnosis of
LCNEC if tumors exhibit only neuroendocrine morphology
or differentiation but not both. In this series, large cell lung
tumors that demonstrated either neuroendocrine morphol-
ogy or differentiation (or both) were considered LCNEC.
Mixed LCNEC tumors were tumors that contained areas of
LCNEC and other histologic subtypes of NSCLC, such as
adenocarcinoma. Although there were only 11 patients in
this series with mixed LCNEC, these tumors were associ-
ated with a 5-year survival that was similar to that for pure
LCNEC and significantly worse than that for LCC. The
finding that mixed LCNEC appears to have the same clin-
ical behavior as LCNEC has also been observed by oth-
ers.4,7,9,14 However, one group found that LCCs with neu-
roendocrine features had a prognosis similar to that of other
histologic subtypes of NSCLC.15 At the cellular level,
LCNEC has a higher proliferative activity than does
LCC,16,17 and expression analysis of p53, Ki-67, K-ras-2,
and C-raf-1 suggested that LCNECs are genetically and
immunohistochemically more similar to SCLCs than
NSCLCs.18,19 These observations might be explanations for
the unfavorable tumor biology associated with LCNEC.
Because of the significantly poorer prognosis associated
with LCNEC and mixed LCNEC in comparison with LCC,
we believe that these histologic variants of NSCLC should
be carefully distinguished pathologically by both light mi-
croscopy and immunohistochemical staining for neuroen-
docrine markers. Identification of somatostatin receptors on
LCNEC in vivo with OctreoScan, indium 11–tagged dieth-
ylenetriamine pentaacetic acid pentreotide scintigraphy,20-22
might represent an opportunity to improve preoperative
staging when LCNEC is suspected or confirmed, as well as
screening for tumor recurrence postoperatively.23 Treatment
of patients with the somatostatin analog octreotide after
surgical resection might also represent a novel adjuvant
biologic therapy because it has been shown to control met-
astatic growth while being well tolerated in the treatment of
other neuroendocrine tumors.24 However, this potential
therapy might be limited because Jiang and colleagues5
identified somatostatin receptor expression by immunohis-
tochemical staining in only 41% of LCNECs.
In an effort to improve cure rates in patients with
LCNEC, postoperative adjuvant chemotherapy or radiother-
apy has been used in several series of this disease.4,8,18,25,26
170 The Journal of Thoracic and Cardiovascular Surgery ● JulyUnfortunately, no study has yet reported a definitive sur-
vival advantage for postoperative adjuvant therapy in these
patients. One series did find a benefit to adjuvant chemo-
therapy in a small subgroup of 5 patients with stage I
disease treated with cisplatin, carboplatin, or cyclophosph-
amide.27 As a result of the small numbers in each study and
the relative infrequency of LCNEC, no standard adjuvant
therapy regimen has been followed. It has been suspected
that these tumors are resistant to conventional chemother-
apy. In a study reported by Lai and coworkers,28 a majority
of lung neoplasms with neuroendocrine markers were found
to express the multidrug resistance gene (MDR1), a harbin-
ger of resistance to chemotherapy. The question of the role
of adjuvant therapy for early-stage LCNEC or mixed
LCNEC should be answered in large-center prospective
trials. A chemotherapy regimen with agents that demon-
strate activity in both NSCLC and SCLC (eg, cisplatin and
etoposide) should be used in these trials.
In conclusion, LCNEC of the lung is an uncommon but
aggressive lung cancer associated with a poor prognosis,
even in patients with stage I disease. Accurate differentia-
tion of these tumors is important in identifying patients who
are most likely to have recurrent lung cancer after surgical
resection. Novel therapeutic approaches will be needed to
improve cure rates in patients with this type of lung cancer.
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Discussion
Dr William H. Warren (Chicago, Ill). I think it is appropriate at
this time to review some of the history of LCNEC, which dates
back considerably longer than one is led to believe on the basis of
the presentation and the article. In 1974, Gewirtz and Yalow
extracted adrenocorticotropic hormone (ACTH) and ACTH-type
substances from a large collection of primary lung carcinomas.
Predictably, the majority of these cases were found to be small cell
The Journal of Thoracicarcinomas, and many of the rest were called “carcinoids.” But
there are also a few LCCs from which ACTH was extracted,
although their endocrine properties were not suspected clinically.
This observation validated earlier case reports of the occasional
LCCs presenting with so-called “ectopic” hormone production.
In 1978, Gould published a series of “undifferentiated carcino-
mas” identified as containing neurosecretory granules, an ultra-
structural hallmark of neuroendocrine differentiation. Before this
study, many of these cases were called simply “large cell undif-
ferentiated carcinoma.”
In 1982, we proposed a classification of neuroendocrine carci-
nomas of the bronchopulmonary tract and proposed the term
“intermediate-sized cell neuroendocrine carcinoma” to describe a
group of tumors (intermediate between giant cell carcinoma and
small cell carcinoma) with demonstrably neuroendocrine, as well
as histologic, features to distinguish them from “large cell undif-
ferentiated carcinoma.”
It has really taken 30 years for us to present an article like this,
identifying the clinical significance of these well-recorded obser-
vations.
You might ask why. I can think of at least 3 reasons. First, I
think LCNEC is an underdiagnosed entity. Indeed, in this series of
more than 2000 cases, only 56 were identified. One reason for this,
ironically, is the very lack of clinical significance. A pathologist
might well argue about why one would go to the trouble of
identifying this subgroup of “large cell carcinomas” if it has no
clinical significance. Therefore, it has become sort of a circular
argument. The second reason is this vexing problem of “multidi-
rectional differentiation,” whereby a tumor can comprised cells
demonstrating simultaneously multiple lines of differentiation.
This phenomenon is common among these tumors, and the authors
alluded to this in their article. What do you call a lung cancer that
comprises large cells, half of which have obvious glandular dif-
ferentiation, adenocarcinoma, and half have demonstrably neu-
roendocrine differentiation? Do these tumors have a different
course than those with predominantly neuroendocrine differentia-
tion? Indeed, what percentage of the tumor has to be neuroendo-
crine to classify it as such? If only 10% of the cells are neuroen-
docrine, should this LCC be distinguished as neuroendocrine?
Last, this diagnosis can only be made currently on the basis of
ideally preserved generous tissue biopsy specimens. It is now
technically possible to immunostain cytologic specimens (both
fine-needle aspirates and fluid samples) for panneuroendocrine
markers. Can we expect the pathologist to provide this diagnosis
on the basis of a minimal biopsy specimen? This goes back to my
first point that this is an underdiagnosed entity.
I have several questions to pose. First, how did you identify
these 56 cases (56 of more than 2000 cases)? Did you only look at
LCC, or did you look at some poorly differentiated adenocarcino-
mas and squamous carcinomas as well?
Dr Battafarano. We looked at all the tumors that were LCCs
and our prospectively gathered database, and actually it was a quite
large number. It was not until we actually looked at the pathologic
slides over that 14-year period that we narrowed in on those
tumors that were large cell within the ones that had neuroendocrine
differentiation or morphology.
Dr Warren. Can you give us any insight into your so-called
mixed tumors? How much is mixed? If it is 10% neuroendocrine
c and Cardiovascular Surgery ● Volume 130, Number 1 171
General Thoracic Surgery Battafarano et al
G
TSand the rest is adenocarcinoma, is that a mixed tumor? If it is 90%
neuroendocrine and you find a few tonofilaments, is that neuroen-
docrine or mixed neuroendocrine-squamous?
Dr Battafarano. Probably less than 3% of the tumors were
neuroendocrine, and they were included in there. Usually it de-
pends on how aggressively the pathologists look. At our institu-
tion, if they find it, it probably represents a significant portion of
the tumor because they are not doing millimeter slices. It might be
that you would find more tumors if you sliced the tumors more
carefully and really looked for it aggressively.
Dr Warren. Do you agree that this is an underestimation of
this albeit unusual tumor?
Dr Battafarano. Correct.
Dr Warren. Can you comment on whether any of these cases
could have been identified by minimal biopsy, such as fine-needle
aspirate or a bronchial biopsy or serum neuron–specific enolase?
Dr Battafarano. We do not routinely use preoperative needle
biopsy as a group, but 10 patients did have preoperative needle
biopsies. In only 2 of those 10 were the tumors said to be poorly
differentiated and the pathologists were concerned about neuroen-
docrine tumors, but they would not pin it down. For the others,
there were 2 that were SCLCs that we did not believe because it
presented as a solitary pulmonary nodule, and then others they just
called NSCLC and would not differentiate it more closely than
that.
Dr Thomas K. Waddell (Toronto, Ontario, Canada). I en-
joyed that presentation, as I have the series of articles you have
produced over the past couple of years.
What difference does it make once you have this information?
I would like to know what lessons you have learned from your St
Louis experience regarding adjuvant therapy, either adjuvant node
clearance or adjuvant chemotherapy postoperatively. Finally, for
the patients who do have recurrence, what information do you have
about patterns of recurrence, local versus distant?
Dr Battafarano. Essentially we have taken the approach that
many surgeons have taken with this, which is that there is not
much you can do with it anyway, and therefore you just resect and
172 The Journal of Thoracic and Cardiovascular Surgery ● Julyhope for the best. But now, with these new data, I think that we can
clearly tell our patients that if they have neuroendocrine differen-
tiation in their tumor, the likelihood of development of recurrent
disease and dying from that disease is quite high, and I think as a
group we have to start thinking about enrolling these patients in
some sort of adjuvant trial. I do not think a preoperative trial is
practical because the pathologists will not give us the data we need
to call it large cell neuroendocrine disease. But I think an adjuvant
trial is reasonable. At the International Association for the Study of
Lung Cancer last summer, we had a meeting looking at that, in
which we could prospectively enroll patients. I think the adjuvant
chemotherapy to use would be something like etoposide and
platinum. This is something that is used in small cell carcinoma
with good results, if you can call results in small cell carcinoma
good, but at least there are response rates. Also, it is the etoposide-
platinum that we use for our Pancoast tumors preoperatively.
Therefore, it also has a reasonable response rate in patients with
non–small cell cancer. Therefore, I think that that would be the
thing to do.
Dr Tomasz Grodzki (Szczecin, Poland). Thank you for an
extremely interesting and clinically very valuable article.You men-
tioned that adjuvant chemotherapy would be a solution to improve
survival, but could you tell us something more about the possible
mechanisms as to why such a similar carcinoma, slightly different
from LCC, presents such a different prognosis?
Dr Battafarano. It is because of recurrent disease. To answer
Dr Waddell’s question, too, about recurrence rates, they have been
local and distant, and almost all of the patients had distant recur-
rences at the time the disease was diagnosed. Therefore, it is not
just a local problem. When they look at small cell carcinoma and
compare it with LCNEC, at least at the molecular level, when you
look at p53 and K-ras mutations, they are relatively similar.
Therefore, I think that again for this biologic behavior in which the
tumors metastasize more quickly, we assume a micrometastatic
disease must be present at the time that we are redoing our
resections.
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